Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study

被引:307
|
作者
Diamond, Seymour
Bigal, Marcelo E.
Silberstein, Stephen
Loder, Elizabeth
Reed, Michael
Lipton, Richard B.
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA
[2] Montefiore Headache Ctr, Bronx, NY USA
[3] New England Ctr Headache, Stamford, CT USA
[4] Thomas Jefferson Univ Hosp, Jefferson Headache Ctr, Philadelphia, PA USA
[5] Spaulding Rehabil Hosp, Boston, MA USA
[6] Vedanta Res, Chapel Hill, NC USA
[7] Albert Einstein Coll Med, Bronx, NY USA
来源
HEADACHE | 2007年 / 47卷 / 03期
关键词
migraine; prevalence; treatment; prevention;
D O I
10.1111/j.1526-4610.2006.00631.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective.-To describe the patterns of medical treatment for migraineurs in the United States. Background.-Over the past decade, many new treatments for migraine have become available and awareness of migraine has improved. However, there is little information about the patterns of medical treatment in the US society. Design/Methods.-A validated self-administered headache questionnaire was mailed to a random sample of 120,000 US households. Each household member with severe headaches was asked to complete the survey. The questionnaire assessed headache features, disability, and patterns of medical treatment. Subjects were classified according to their use of headache preventive medication, as current users, coincident users (using effective medications for other medical reasons), lapsed users (had used in the past but not at the time of the survey), or never users. Results.-In 162,576 participants, the prevalence of migraine was 17.1% in women and 5.6% in men. Only 56.2% of those with migraine had ever received a medical diagnosis. Ninety-eight percent of the migraineurs used acute treatment for their migraine attacks. Forty-nine percent (49%) usually used over-the-counters, 20% usually used prescription medications, and 29% used both. Only 12.4% of migraineurs indicated that they were taking a migraine preventive medication, but 17.2% were using medications with potential antimigraine effects for other medical reasons. Current or past use of preventive medication was more likely in women than men (odds ratio [OR] = 1.37, 95% confidence interval [CI] 1.27-1.48), increased with age and individuals with high MIDAS grade (Grade IV vs I, OR 2.35, 95% CI 2.09-2.64). Preventive medication use increased with awareness of migraine and with illness severity. Conclusions.-Migraine remains undertreated in the US population. Barriers to preventive treatment are greater in younger age groups, men, and people unaware that they have migraine.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 50 条
  • [1] Probable migraine in the United States: Results of the American Migraine Prevalence and Prevention (AMPP) Study
    Silberstein, S.
    Loder, E.
    Diamond, S.
    Reed, M. L.
    Bigal, M. E.
    Lipton, R. B.
    CEPHALALGIA, 2007, 27 (03) : 220 - 229
  • [2] Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study
    RB Lipton
    AN Manack
    D Serrano
    DC Buse
    The Journal of Headache and Pain, 2013, 14
  • [3] Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study
    Lipton, R. B.
    Manack, A. N.
    Serrano, D.
    Buse, D. C.
    JOURNAL OF HEADACHE AND PAIN, 2013, 14
  • [4] Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study
    Lipton, Richard B.
    Munjal, Sagar
    Buse, Dawn C.
    Bennett, Alix
    Fanning, Kristina M.
    Burstein, Rami
    Reed, Michael L.
    HEADACHE, 2017, 57 (07): : 1026 - 1040
  • [5] Prevalence and burden of migraine in the United States: Data from the American Migraine Study II
    Lipton, RB
    Stewart, WF
    Diamond, S
    Diamond, ML
    Reed, M
    HEADACHE, 2001, 41 (07): : 646 - 657
  • [6] Acute Treatment Optimization in Episodic and Chronic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study
    Serrano, Daniel
    Buse, Dawn C.
    Adams, Aubrey Manack
    Reed, Michael L.
    Lipton, Richard B.
    HEADACHE, 2015, 55 (04): : 502 - 518
  • [7] Migraine diagnosis and treatment: Results from the American Migraine Study II
    Lipton, RB
    Diamond, S
    Reed, M
    Diamond, ML
    Stewart, WF
    HEADACHE, 2001, 41 (07): : 638 - 645
  • [8] A Review of Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results From the American Migraine Prevalence and Prevention Study
    Krasenbaum, Lynda J.
    HEADACHE, 2017, 57 (07): : 1156 - 1157
  • [9] Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study
    Buse, Dawn C.
    Manack, Aubrey N.
    Fanning, Kristina M.
    Serrano, Daniel
    Reed, Michael L.
    Turkel, Catherine C.
    Lipton, Richard B.
    HEADACHE, 2012, 52 (10): : 1456 - 1470
  • [10] Economic Burden of Transformed Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study
    Munakata, Julie
    Hazard, Elisabeth
    Serrano, Daniel
    Klingman, David
    Rupnow, Marcia F. T.
    Tierce, Jonothan
    Reed, Michael
    Lipton, Richard B.
    HEADACHE, 2009, 49 (04): : 498 - 508